Celyad Oncology SA (EBR:CYAD)
Belgium · Delayed Price · Currency is EUR 0.2700
+0.0140 (5.47%)
Aug 11, 2026, 12:31 PM CET
Celyad Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.02 | 0.19 | 0.1 | - | - | |
Revenue Growth | -88.71% | 82.35% | 1940.00% | - | - |
Cost of Revenue | 0.01 | 0.01 | 0.07 | - | - |
Gross Profit | 0.01 | 0.17 | 0.03 | - | - |
Selling, General & Admin | 3.78 | 3.2 | 6.03 | 10.55 | 9.91 |
Research & Development | 3.42 | 3.24 | 4.6 | 18.93 | 20.77 |
Other Operating Expenses | 0.19 | 0.04 | 0.19 | 35.42 | 1.47 |
Total Operating Expenses | 7.39 | 6.47 | 10.82 | 64.9 | 32.15 |
Operating Income | 0.88 | -5.86 | -8.46 | -40.86 | -26.39 |
Interest Income | 0.01 | 0.15 | 0.03 | 0.19 | 0.14 |
Interest Expense | -0.06 | -0.12 | -0.08 | -0.2 | -0.26 |
Other Non-Operating Income (Expense) | 8.26 | 0.44 | 2.33 | 24.04 | 5.76 |
Total Non-Operating Income (Expense) | 8.2 | 0.47 | 2.28 | 24.03 | 5.65 |
Pretax Income | 0.83 | -5.82 | -8.51 | -40.87 | -26.5 |
Provision for Income Taxes | - | - | 0.06 | -0.07 | -0.01 |
Net Income | 0.83 | -5.82 | -8.45 | -40.94 | -26.51 |
Net Income to Common | 0.83 | -5.82 | -8.45 | -40.94 | -26.51 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 43 | 41 | 26 | 23 | 16 |
Shares Outstanding (Diluted) | 43 | 41 | 26 | 23 | 16 |
Shares Change | 3.26% | 61.06% | 13.84% | 44.80% | 11.92% |
EPS (Basic) | 0.02 | -0.14 | -0.33 | -1.81 | -1.70 |
EPS (Diluted) | 0.02 | -0.14 | -0.33 | -1.81 | -1.70 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.9 | -5.68 | -16.1 | -28.13 | -26.97 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Per Share | -0.16 | -0.14 | -0.63 | -1.25 | -1.73 |
Gross Margin | 61.90% | 93.01% | 32.35% | - | - |
Operating Margin | 4195.24% | -3149.46% | -8291.18% | - | - |
Profit Margin | 3952.38% | -3131.18% | -8282.35% | - | - |
FCF Margin | -32857.10% | -3053.76% | -15785.30% | - | - |
EBITDA | 1.05 | -5.41 | -7.66 | -39.42 | -24.87 |
EBITDA Margin | 5014.29% | -2907.53% | -7512.75% | - | - |
EBIT | 0.88 | -5.86 | -8.46 | -40.86 | -26.39 |
EBIT Margin | 4195.24% | -3149.46% | -8291.18% | - | - |
Effective Tax Rate | 0.00% | 0.00% | -0.74% | 0.16% | 0.04% |